Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Taiho Pharmaceutical
Biotech
UPDATED: Taiho’s discontinues ph. 3 trial after DMD miss
Taiho said both cohorts of the trial have been discontinued and that it is considering all possibilities regarding the future of TAS-205.
Gabrielle Masson
Jul 8, 2025 10:17am
ASCO: Cullinan drug sees 35% ORR in pretreated NSCLC
May 22, 2025 5:00pm
Otsuka's Taiho pays $400M to buy Swiss ADC partner
Mar 17, 2025 8:10am
Cullinan plans approval push for NSCLC drug after ph. 2 win
Jan 29, 2025 6:15am
Taiho pays to claw back licensing rights to lung cancer med
May 12, 2022 3:00am
Taiho Pharma, Cullinan Oncology join forces on EGFR drug
Feb 5, 2019 10:51am
